NCT06746896Active, not recruiting
Retrospective Study on the Role of SCFA Modulation in Multiple Sclerosis
A Retrospective Study on the Role of Short-chain Fatty Acids Modulation in Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 30 Dec 2024
Brief summary (registry, in English)
Recent studies show that gut microbiota strongly influences multiple sclerosis. These data suggest that the microbiota could have a direct effect on MS pathogenesis, although the mechanisms through which it modulates central nervous system (CNS) neuroinflammation and neurodegeneration are still poorly defined. The microbiota mediates its action principally through synthesizing specific metabolites that act as messengers in host functions, such as the modulation of the immune and nervous system, tissue repair, and stemness. The short-chain fatty acids (SCFAs- mainly acetate, propionate, and butyrate), produced by the fermentation of dietary fibers, are a class of microbial metabolites of primary importance for host physiology. Thus, the objective is to establish a mechanistic link between gut microbiota dysbiosis, reflected by a different level of SCFAs and SCFA-producing bacteria species, and neuroimmune alterations in MS. Preliminary data show a differential metabolomic profile in urine samples of MS patients compared to healthy controls. The authors now aim at deepening previous findings by analysing also the SCFAs concentration in the urines, plasma and CSF by GC-MS (their level turned out to be too low to be measured by NMR) and the microbiota composition by shotgun metagenomics analysis, to track changes in the abundance of SCFAs-producing bacteria species.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 18 Dec 2024
- Start date
- 17 Nov 2021
- Primary completion date
- 24 Nov 2022
- Lead sponsor
- Prof. Massimo Filippi
- Diseases
- Multiple sclerosis
- NCT number
- NCT06746896
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 17 Nov 2021 to the primary completion date, 24 Nov 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- None
Who the study is looking for
- \- Volunteers that have preventively signed the informed consent to use their samples for additional studies.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS San Raffaele Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.